Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.
Yijiao XuQingwei ZhangZhisheng ChenShuwen YangHaiyan ChenXiong XiaoHongni JiangPublished in: BMC pulmonary medicine (2024)
For NSCLC patients with a positive T-SPOT response undergoing ICIs treatment, our study observed indications of active tuberculosis. The varied T-SPOT spot count changes post-ICIs treatment suggest a complex interaction, potentially linking T-SPOT spot count reduction to tuberculosis reactivation risk. These preliminary findings underscore the importance of further research to more accurately assess T-SPOT's diagnostic utility in this context.
Keyphrases
- small cell lung cancer
- end stage renal disease
- mycobacterium tuberculosis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- stem cells
- emergency department
- peripheral blood
- dendritic cells
- prognostic factors
- high throughput
- peritoneal dialysis
- bone marrow
- cell therapy
- brain metastases
- patient reported outcomes
- adverse drug
- smoking cessation